RxSight launches newest Light Adjustable Lens

RxSight, Inc. announced the U.S. commercial launch of the latest version of its Light Adjustable Lens (LAL): LAL+, which the company is marketing as the next installment of the first and only customizable intraocular lens (IOL) for cataract surgery.

Let’s start with RxSight.

Based in Aliso Viejo, California, the ophthalmic medical technology corporation is looking to advance cataract surgery via a unique line of IOLs.

Its flagship product: the LAL.

Tell me about the LAL.

The original LAL was developed as the first and only lens able to be adjusted in the eye following cataract surgery.

Implanted via a standard cataract procedure, the LAL allows surgeons to adjust the lens for a patient over a series of treatments to ensure its specific fit.

Per the company, each adjustment is an ultraviolet (UV) light treatment performed using its proprietary Light Delivery Device (LDD) to correct refractive error and dial into optimized vision.

The intended result: customized and clear vision, with the “best-corrected visual acuity (BCVA) at all distances.”

Explain this LDD.

The LDD administers carefully controlled beams of UV to a patient’s eyes, ensuring that all macromers in the beam’s path link up to form polymers.

This movement of refracting to the UV beam leads to “predictable changes” in the lens’ curvature and refraction strength.

What kind of correction does it offer?

Per RxSight, the lens corrects down to 0.5 D of astigmatism—the lowest level approved for treatment.

The company noted that, based on research, this level of astigmatism can “reduce visual acuity (VA) by one line, and the impact on dynamic, functional (VA) and low-contrast acuity is even greater.”

Which patients is this lens ideal for?

Ideally, for post-LASIK patients or those who prefer monovision.

Alrighty, now what does this updated LAL offer?

While the LAL+ is built on the same platform as the LAL, this new lens has a modified aspheric anterior surface that provides a “small continuous increase in central lens power, which is designed to slightly extend the depth of focus (DOF),” according to RxSight.

What else does it include?

As with the original LAL, the LAL+ also features RxSight’s ActivShield technology, which provides a layer of UV protection built right into the lens.

Another added benefit: This tech works to prevent unintentional sunlight exposure from changing the lens prior to the final lock-in treatment. See below for a visual.

What’s the clinical data on it?

Funny you should ask. The LAL and LAL+ were recently the topics of interest in a number of sessions presented during the 2024 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting this past weekend.

Click here for a look at those presentation findings.

Give me a sneak peek of those results.

We’ll call out one particular study:

Assessing Binocular Vision Post-Implantation with a Newly Approved Light Adjustable Lens with a Modified Aspheric Anterior Surface
- Presented by T. Hunter Newsom, MD, ABO
Its purpose: to assess the vision and visual performance of 120 bilateral cataract patients (220 eyes) who received the LAL+ via bilateral implantation
The setup: All eyes underwent small-incision phacoemulsification after LAL+ implantation; at 2 months postop, UV light caused a targeted refractive change to the IOL
The outcome measures: collected and compared to the original LAL at 2 months post-secondary eye implant:
- Monocular and binocular uncorrected-distance VA (UCDVA) across distances, subjective manifest refraction, and vision quality
The findings:
- Overall: the LAL+ demonstrated comparable distance and vision quality outcomes to the original LAL.
  - The numbers:
    - +80% achieved a CDVA of 20/20 or better
    - 94% achieved a MRSE within ± 0.50 D
    - All participants had a mean residual cylinder of 0.2D

And compared to the original LAL?

Notably, the results showed that “ this new LAL showcased a marked improvement in both intermediate and near vision compared to the current LAL model by improving over a half a line intermediate vision and over a line of near vision.”

Now the conclusion.

Based on the data, this presentation stated that, while the original LAL demonstrated “excellent outcomes due to its adjustability, the newly approved LAL elevates intermediate and near vision performance” without comprising distance and overall vision quality.

Lastly ... where can I purchase this for my clinic?

Click here (and scroll all the way down) to request details.